Skip to content

The objective of this study will be to evaluate the dermatological safety of investigational products through primary irritation patch test on healthy human volunteers with sensitive skin.

To evaluate the dermatological safety of investigational products by primary irritation patch test on healthy human volunteers of with sensitive skin - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/054003
Enrollment
35
Registered
2023-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Leave on (14-133):Product A: 1:1 slurry solution of the investigational product will be prepared by weighing 5g of the product & dissolving it in 5 ml of distilled water. Mix it slowly

Sponsors

ITC LIMITED ITC Life Sciences and Technology Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female and male Asian Indian subjects. 2.Healthy human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup). 3.Between 18 and 65 years of age. 4.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….). 5.Specific Criteria -Subjects representing sensitive skin type (Subjects scoring greater than 30 for Section 2- Sensitive vs Resistant skin in Dr. Baumann’s questionnaire, please refer appendix 4) and varied skin type (ideally equal representation of all 4 skin types – Oily, Normal, Dry and Combination). -Subjects who have not participated in a similar investigation in the past eight weeks.

Exclusion criteria

Exclusion criteria: 1.Standard criteria -For female: Currently established to be pregnant or actively breast feeding or has recently stopped breast feeding -Having refused to give his/her assent by signing the consent form. - Currently participating in another study that is liable to interfere with this study. -Being diabetic. -Being asthmatic. -Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). - Subjects with chronic illness that may influence the cutaneous state or any other illness including Diabetes, liver disease, HIV or any other serious medical illness. -Subjects with cutaneous disease that could interfere with the study results. -Having a diagnosed or highly probable allergy to one or several compounds of cosmetic products. -Having undergone surgery requiring general anesthesia of more than one hour in the past 6 months. -Having changed his/her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit. -Having applied some product on the back thus not meeting the study requirement. -No individual sentenced to imprisonment by a court decision or by an administrative decision, or hospitalized without consent, or admitted in a medical or social establishment. - No minor as well as individual of age benefiting from a legal protection measure or enable to express his/her consent 2.Refusing to follow the restrictions mentioned below during the study: - For female: Avoid pregnancy or active breastfeeding. - Abstain from participation in another study liable to interfere with this study. - Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). - Do not change cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit. 3.Specific criteria - Having eczema, psoriasis, lichen planus, vitiligo etc. in the concerned area. -Having healing disorder in the concerned area. -Having rhinitis, allergic conjunctivitis, or rhino sinusitis. -Having an allergy to perfumes and/or preservatives in cosmetic products. -Having an allergy to plaster / adhesives used in plaster. - Having a food allergy. -Having a cardiovascular pathology that requires beta blocking treatments. -Having immunosuppressive drugs, such as cyclophosphamide, methotrexate, azathioprine, etc. -Taking a retinoid-based treatment by general or oral route. -Taking specific treatment on the back. - Having taken an anti-histaminic treatment in the last 2 weeks preceding the start of the study. – Having miliaria (prickly heat) on the back. - Presenting too many neavi on the back. - Having high pilosity on the back. 4. Refusing to follow the restrictions below during the study: - During the first 24 hours (after patch application), neither cosmetic products nor water must be applied on the back. - Till the follow up period of until T8 days, only water is accepted from the fir

Design outcomes

Primary

MeasureTime frame
Dermatological safety / Irritation potential on skinTimepoint: Baseline,0 hrs,24 hrs & 7 days

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

raji@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026